Lon­za boosts ADC sup­ply ca­pac­i­ty through part­ner­ship ex­pan­sion with un­named ma­jor phar­ma

Af­ter a sum­mer of com­mer­cial and team trou­bles, there’s some good news for Lon­za as it ex­tends its part­ner­ship with an un­named “ma­jor bio­phar­ma­ceu­ti­cal part­ner” to en­hance its an­ti­body-drug con­ju­gate man­u­fac­tur­ing ca­pa­bil­i­ties.

The ex­ten­sion builds on an ex­ist­ing col­lab­o­ra­tion be­tween Lon­za and the se­cret phar­ma com­pa­ny for end-to-end ADC man­u­fac­tur­ing at Lon­za’s Ibex Ded­i­cate Biopark site in Visp, Switzer­land. The deal cov­ers pay­load and mon­o­clon­al an­ti­body man­u­fac­tur­ing as well as bio­con­ju­ga­tion — the process where­by these two parts are co­va­lent­ly linked.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.